Several pan glutamine-deamidase inhibitors (e.g. azaserine and 6-diazo-5-oxo-L-norleucine), which potently suppress GFAT activity, have demonstrated anti-tumor activity in vitro and in vivo in PDA and other cancers (Leone et al., 2019; Sharma et al., 2020). Here, GFPT1 is linked to neoplasm.